

Supplementary information

Engineering precision nanoparticles for drug delivery

In the format provided by the authors and unedited

2020 Competing Interests Disclosure

From FY 2015 to the present, Dr. Robert Langer receives licensing fees (to patents in which he was an inventor on) from, invested in, consults (or was on Scientific Advisory Boards or Boards of Directors) for, lectured (and received a fee), or conducts sponsored research at MIT for which he was not paid for the following entities:

1. 7th Sense;
2. Abpro Labs;
3. Abpro-Korea;
4. Acorda (Formerly Civitas Therapeutics);
5. Aleph Farms;
6. Alivio Therapeutics;
7. Alkermes;
8. Allevi;
9. Alnylam Pharmaceuticals, Inc;
10. Apotex;
11. Arcadia Biosciences, Inc;
12. Arsenal Medical;
13. Artificial Cell Technology, Inc;
14. Avalon-Globocare;
15. BASF Corporation;
16. Biogen;
17. BioInnovation Institute (Novo Nordisk Founden);
18. Blackstone (Formerly Clarus);
19. Boston Children's Hospital;
20. Celero;
21. Cellomics Technology, Llc;
22. Cellular Biomedical;
23. Charles River Laboratories, Inc.;
24. Clontech Laboratories;
25. Combined Therapeutics ("CTx");
26. Conference Forum;
27. Cornell University;
28. Crispr Therapeutics Ag;
29. Crown Bioscience Inc.;
30. Cygnal Therapeutics, Inc.;
31. Daros, Inc.
32. Dare Biosciences (Formerly Microchips Biotech, Juniper Pharmaceuticals, and Columbia Laboratories);
33. DeepBiome;
34. Dewpoint Therapeutics;
35. Dispendix/ Cellink;
36. Domain;
37. Eagle Pharmaceuticals;
38. Edigene Biotechnology, Inc.;
39. Editas Medicine, Inc.;
40. Eli Lilly;
41. Eisai Inc.;
42. Entrega;
43. Everlywell;
44. Evox Therapeutics, Ltd.;
45. Flagship Pioneering;
46. Frequency Therapeutics, Inc.;
47. Genemedicine Co Lmted;
48. GenScript USA Inc;
49. GENUV;
50. Glaxosmithkline Llc;
51. Glycobia;
52. Glympse Bio;
53. Greenlight Biosciences;
54. HCR (HealthCare Royalty Partners);
55. Hopewell Therapeutics;
56. Horizon Discovery Group Plc;
57. Humacyte, Inc.;
58. IBEX Pharmaceuticals, Inc.;
59. ImmuneXcite Inc.;
60. Indivor;
61. Institute of Immunology Co. Ltd;
62. Integrated Dna Technologies, Inc.;
63. InVivo Therapeutics;
64. IxBio;
65. J.R. Simplot Company;

2020 Competing Interests Disclosure

From FY 2015 to the present, Dr. Robert Langer receives licensing fees (to patents in which he was an inventor on) from, invested in, consults (or was on Scientific Advisory Boards or Boards of Directors) for, lectured (and received a fee), or conducts sponsored research at MIT for which he was not paid for the following entities:

66. Jnana Therapeutics;
67. Kala Pharmaceuticals;
68. Kallyope, Inc.;
69. Kensa;
70. Kodikaz Therapeutics
71. Ksq Therapeutics, Inc.;
72. Landsdowne Labs;
73. LikeMinds;
74. Luminopia, Inc.;
75. Luye (Shandong luye);
76. Lyndra Therapeutics;
77. Lyra Therapeutics (Formerly "480 Biomedical");
78. McGovern Institute;
79. Medikinetics Co., Ltd.;
80. Merck;
81. MGH Ragon Institute;
82. Micelle;
83. Moderna Therapeutics;
84. Momenta;
85. Monsanto Company;
86. Muse Biotechnologies Inc.
87. Mylan;
88. Nanobiosym;
89. Nanobiotix;
90. Newbridge Ventures LLC;
91. Noveome Biotherapeutics, Inc.;
92. Novo Nordisk;
93. Particles for Humanity;
94. Pfizer, Inc.;
95. Pioneer Hi-Bred International, Inc.;
96. Polaris Partners;
97. Portal Instruments;
98. Preceres, Llc (Acquired by Monsanto);
99. Pulmatrix;
100. PureTech;
101. ReLive;
102. Reprocell Usa, Inc. (Formerly Stemgent);
103. Rubius Therapeutics;
104. Secant Medical, Inc.;
105. Seer, Inc.;
106. Selecta Biosciences;
107. Senses LLC;
108. Setsuro Tech Inc.;
109. Seventh Sense Biosystems, Inc.;
110. Shenzhen Rice Life Technology, Ltd;
111. Shire Ag;
112. Siglion;
113. Sigma Aldrich Co. Llc;
114. Sio2;
115. Ske S.R.L.;
116. Soil Culture Solutions Llc (Dba Soilcea);
117. SQZ Biotechnologies;
118. StemBioSys, Inc.;
119. SuonoBio;
120. T2 Biosystems;
121. Taconic Biosciences, Inc. (formerly Taconic Farms);
122. TARA;
123. Tarveda Therapeutics;
124. Tesio Pharmaceuticals
125. Third Rock;
126. Tiba Biotech Llc;
127. Tissium (formerly"Gecko");
128. Transgenic Inc.;
129. Translate Bio (Formerly Rana Therapeutics, Inc.);
130. Trilink Biotechnologies, Inc.;
131. Unilever (Living Proof);

2020 Competing Interests Disclosure

From FY 2015 to the present, Dr. Robert Langer receives licensing fees (to patents in which he was an inventor on) from, invested in, consults (or was on Scientific Advisory Boards or Boards of Directors) for, lectured (and received a fee), or conducts sponsored research at MIT for which he was not paid for the following entities:

132. VasoRX;
133. Verseau Therapeutics, Inc.;
134. Vivtex Corporation;
135. Whitehead Institute;
136. Wiki Foods;
137. Yz Biosciences (Guangzhou) Inc.;
138. Zenomics;